Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO.sub.3—), sulfuric acid group (—OSO.sub.3—), carboxylic group (—CO.sub.2—), phosphonic acid group (—OPO.sub.3.sup.2—), phosphate group (—OPO.sub.3.sup.2—), and sulfamic acid group (—NHSO.sub.3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

A water-soluble conjugated polymer for photothermal therapy, a polymerized monomer thereof, a preparation method therefor, and application thereof. The water-soluble conjugated polymer has good solubility in an aqueous solution, has excellent biocompatibility, does not need to be subjected to coating treatment, can be directly used for photothermal therapy, is easy to use, has a nanometer size, and can enter cells easily. Polar groups are contained in side chains, and the water-soluble conjugated polymer is capable of targeting, can locate intracellular organelles, has excellent photostability and chemical properties as well as high photothermal conversion efficiency, can achieve photothermal therapy of near-infrared region I or II, with high treatment efficiency and few side effects. In the preparation method for the water-soluble conjugated polymer, raw materials can be easily obtained, synthesis conditions are mild, and the purification is convenient. The preparation method is simple, can be easily implemented, and has a great application prospect.

An iterative approach to dynamic covalent polymerizations of elemental sulfur with functional comonomers to prepare sulfur prepolymers that can further react with other conventional, commercially available comonomers to prepare a wider class of functional sulfur polymers. This iterative method improves handling, miscibility and solubility of the elemental sulfur, and further enables tuning of the sulfur polymer composition. The sulfur polymers may be a thermoplastic or a thermoset for use in elastomers, resins, lubricants, coatings, antioxidants, cathode materials for electrochemical cells, and polymeric articles such as polymeric films and free-standing substrates.

An iterative approach to dynamic covalent polymerizations of elemental sulfur with functional comonomers to prepare sulfur prepolymers that can further react with other conventional, commercially available comonomers to prepare a wider class of functional sulfur polymers. This iterative method improves handling, miscibility and solubility of the elemental sulfur, and further enables tuning of the sulfur polymer composition. The sulfur polymers may be a thermoplastic or a thermoset for use in elastomers, resins, lubricants, coatings, antioxidants, cathode materials for electrochemical cells, and polymeric articles such as polymeric films and free-standing substrates.

The present disclosure provides a pH-sensitive membranolytic polymer material and a preparation method and application thereof. The pH-sensitive membranolytic polymer material has the structure shown in Formula (I). At normal physiological pH, the polymer material is hydrophobic neutral, and can be self-assembled into PEG coated nanoparticles with weak interaction with cell membrane; when the pH decreases, the polymer material can be protonated to form an amphiphilic structure consisting of hydrophobic domain and cationic domain, which has strong interaction with the cell membrane and strong membranolytic activity, so the polymer material can kill tumor cells or bacteria efficiently and selectively.

##STR00001##

The present disclosure provides a pH-sensitive membranolytic polymer material and a preparation method and application thereof. The pH-sensitive membranolytic polymer material has the structure shown in Formula (I). At normal physiological pH, the polymer material is hydrophobic neutral, and can be self-assembled into PEG coated nanoparticles with weak interaction with cell membrane; when the pH decreases, the polymer material can be protonated to form an amphiphilic structure consisting of hydrophobic domain and cationic domain, which has strong interaction with the cell membrane and strong membranolytic activity, so the polymer material can kill tumor cells or bacteria efficiently and selectively.

##STR00001##

A water-soluble polymer having an aliphatic polycarbonate backbone, a first carbonate monomer with at least one hydrophilic functionality, and a second carbonate monomer with at least one hydrophobic functionality is able to completely and quickly eliminate a virus from a human and/or animal cell. The at least one hydrophilic functionality is a sulfate, a sulfonate, a carboxylate, and/or a phosphate and the at least one hydrophobic functionality is an alkyl. The hydrophilic/hydrophobic functionalities of the polymer may be tuned to enhance the antiviral properties of the polymer and/or to decrease any cytotoxicity associated with the application of the polymer to a human and/or animal cell. The antiviral polymer is biocompatible and biodegradable.

A water-soluble polymer having an aliphatic polycarbonate backbone, a first carbonate monomer with at least one hydrophilic functionality, and a second carbonate monomer with at least one hydrophobic functionality is able to completely and quickly eliminate a virus from a human and/or animal cell. The at least one hydrophilic functionality is a sulfate, a sulfonate, a carboxylate, and/or a phosphate and the at least one hydrophobic functionality is an alkyl. The hydrophilic/hydrophobic functionalities of the polymer may be tuned to enhance the antiviral properties of the polymer and/or to decrease any cytotoxicity associated with the application of the polymer to a human and/or animal cell. The antiviral polymer is biocompatible and biodegradable.

Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of —OH groups, (ii) a plurality of thio-functional groups —R.sup.1—SH wherein R.sup.1 is an ester-containing linker, and (iii) optionally one or more —OC(O)—(C.sub.1-C.sub.6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.

Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of —OH groups, (ii) a plurality of thio-functional groups —R.sup.1—SH wherein R.sup.1 is an ester-containing linker, and (iii) optionally one or more —OC(O)—(C.sub.1-C.sub.6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.